Editorial Comment to Prognostic significance of visceral obesity in patients with advanced renal cell carcinoma undergoing nephrectomy

1. Cohen HT, McGovern FJ. Renal-cell carcinoma. N. Engl. J. Med. 2005; 353: 2477–90. 2. DeVita VT Jr, Hellman S, Rosenberg SA. Cancer Principles and Practice of Oncology. 8th edn. Lippincott Williams & Wilkins, Philadelphia, PA, 2008. 3. Bergstrom A, Hsieh CC, Lindblad P, Lu CM, Cook NR, Wolk A. Obesity and renal cell cancer--a quantitative review. Br. J. Cancer 2001; 85: 984–90. 4. Awakura Y, Nakamura E, Ito N et al. Influence of body mass index on prognosis of Japanese patients with renal cell carcinoma. Urology 2007; 70: 50–4. 5. Haferkamp A, Pritsch M, Bedke J et al. The influence of body mass index on the long-term survival of patients with renal cell carcinoma after tumour nephrectomy. BJU Int. 2008; 101: 1243–6. 6. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat. Rev. Cancer 2011; 11: 886–95. 7. Naya Y, Zenbutsu S, Araki K et al. Influence of visceral obesity on oncologic outcome in patients with renal cell carcinoma. Urol. Int. 2010; 85: 30–6. 8. Parker AS, Lohse CM, Cheville JC, Thiel DD, Leibovich BC, Blute ML. Greater body mass index is associated with better pathologic features and improved outcome among patients treated surgically for clear cell renal cell carcinoma. Urology 2006; 68: 741–6. 9. Kuk JL, Lee S, Heymsfield SB, Ross R. Waist circumference and abdominal adipose tissue distribution: influence of age and sex. Am. J. Clin. Nutr. 2005; 81: 1330–4. 10. Kvist H, Chowdhury B, Sjostrom L, Tylen U, Cederblad A. Adipose tissue volume determination in males by computed tomography and 40K. Int. J. Obes. 1988; 12: 249–66. 11. Doyle SL, Donohoe CL, Lysaght J, Reynolds JV. Visceral obesity, metabolic syndrome, insulin resistance and cancer. Proc. Nutr. Soc. 2012; 71: 181–9. 12. Allott EH, Lysaght J, Cathcart MC et al. MMP9 expression in oesophageal adenocarcinoma is upregulated with visceral obesity and is associated with poor tumour differentiation. Mol. Carcinog. 2013; 52: 144–54. 13. Yoshizumi T, Nakamura T, Yamane M et al. Abdominal fat: standardized technique for measurement at CT. Radiology 1999; 211: 283–6. 14. Edge SB BD, Compton CC, Fritz AG, Greene FL, Trotti A. American joint committee on cancer (AJCC) staging manual. 7th edn. Springer, Philadelphia, 2008. 15. Zheng W, McLerran DF, Rolland B et al. Association between body-mass index and risk of death in more than 1 million Asians. N. Engl. J. Med. 2011; 364: 719–29. 16. Kobayashi J, Tadokoro N, Watanabe M, Shinomiya M. A novel method of measuring intra-abdominal fat volume using helical computed tomography. Int. J. Obes. Relat. Metab. Disord. 2002; 26: 398–402. 17. Cecchini S, Cavazzini E, Marchesi F, Sarli L, Roncoroni L. Computed tomography volumetric fat parameters versus body mass index for predicting shortterm outcomes of colon surgery. World J. Surg. 2011; 35: 415–23. 18. Tan W, Hildebrandt MA, Pu X et al. Role of inflammatory related gene expression in clear cell renal cell carcinoma development and clinical outcomes. J. Urol. 2011; 186: 2071–7. 19. Waalkes S, Merseburger AS, Kramer MW et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Causes Control 2010; 21: 1905–10. 20. Donat SM, Salzhauer EW, Mitra N, Yanke BV, Snyder ME, Russo P. Impact of body mass index on survival of patients with surgically treated renal cell carcinoma. J. Urol. 2006; 175: 46–52. 21. Park YH, Lee JK, Kim KM et al. Visceral obesity in predicting oncologic outcomes of localized renal cell carcinoma. J. Urol. 2014; 192: 1043–9. 22. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol. Scand. 2005; 184: 285–93. 23. Rasmuson T, Grankvist K, Jacobsen J, Olsson T, Ljungberg B. Serum insulinlike growth factor-1 is an independent predictor of prognosis in patients with renal cell carcinoma. Acta Oncol. 2004; 43: 744–8. 24. La Cava A, Alviggi C, Matarese G. Unraveling the multiple roles of leptin in inflammation and autoimmunity. J. Mol. Med. (Berl.) 2004; 82: 4–11. 25. Morgan TM, Tang D, Stratton KL et al. Preoperative nutritional status is an important predictor of survival in patients undergoing surgery for renal cell carcinoma. Eur. Urol. 2011; 59: 923–8. 26. Kim HL, Belldegrun AS, Freitas DG et al. Paraneoplastic signs and symptoms of renal cell carcinoma: implications for prognosis. J. Urol. 2003; 170: 1742–6. 27. Steffens S, Grunwald V, Ringe KI et al. Does obesity influence the prognosis of metastatic renal cell carcinoma in patients treated with vascular endothelial growth factor-targeted therapy? Oncologist 2011; 16: 1565–71. 28. Ladoire S, Bonnetain F, Gauthier M et al. Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents. Oncologist 2011; 16: 71–81. 29. Bjorntorp P. Metabolic difference between visceral fat and subcutaneous abdominal fat. Diabetes Metab. 2000; 26(Suppl 3): 10–2. 30. Kashihara H, Lee JS, Kawakubo K, Tamura M, Akabayashi A. Criteria of waist circumference according to computed tomography-measured visceral fat area and the clustering of cardiovascular risk factors. Circ. J. 2009; 73: 1881–6.